Unfortunately, when tested in a clinical trial (NCT00992186), the monoclonal antibody used to target CCL2 failed to induce long-term suppression of serum CCL2, resulting in no effect on tumor growth (247, 248). The gene discussed is CCL2; the disease is neoplasm.